The consequences of hydroxyl radical formation on the stoichiometry and kinetics of ferrous iron oxidation by human apoferritin.
Despite previous detection of hydroxyl radical formation during iron deposition into ferritin, no reports exist in the literature concerning how it might affect ferritin function. In the present study, hydroxyl radical formation during Fe(II) oxidation by apoferritin was found to be contingent on the "ferroxidase" activity (i.e., H subunit composition) exhibited by apoferritin. Hydroxyl radical formation was found to affect both the stoichiometry and kinetics of Fe(II) oxidation by apoferritin. The stoichiometry of Fe(II) oxidation by apoferritin in an unbuffered solution of 50 mM NaCl, pH 7.0, was approximately 3.1 Fe(II)/O(2) at all iron-to-protein ratios tested. The addition of HEPES as an alternate reactant for the hydroxyl radical resulted in a stoichiometry of about 2 Fe(II)/O(2) at all iron-to-protein ratios. HEPES functioned to protect apoferritin from oxidative modification, for its omission from reaction mixtures containing Fe(II) and apoferritin resulted in alterations to the ferritin consistent with oxidative damage. The kinetic parameters for the reaction of recombinant human H apoferritin with Fe(II) in HEPES buffer (100 mM) were: K(m) = 60 microM, k(cat) = 10 s(-1), and k(cat)/K(m) = 1.7 x 10(5) M(-1) x (-1). Collectively, these results contradict the "crystal growth model" for iron deposition into ferritin and, while our data would seem to imply that the ferroxidase activity of ferritin is adequate in facilitating Fe(II) oxidation at all stages of iron deposition into ferritin, it is important to note that these data were obtained in vitro using nonphysiologic conditions. The possibility that these findings may have physiological significance is discussed.
Van Eden
M E
ME
Department of Chemistry and Biochemistry, Utah State University, Logan, UT 84322-4705, USA.
Aust
S D
SD
D001052:Apoferritins / Q000737:chemistry / Q000378:metabolism*; D002570:Ceruloplasmin / Q000187:drug effects / Q000378:metabolism*; D004789:Enzyme Activation / Q000502:physiology; D005290:Ferric Compounds / Q000378:metabolism*; D005609:Free Radicals / Q000378:metabolism; D006531:HEPES / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D017665:Hydroxyl Radical / Q000378:metabolism*; D007501:Iron / Q000378:metabolism*; D007700:Kinetics; D010084:Oxidation-Reduction / Q000187:drug effects; D011485:Protein Binding / Q000502:physiology; D011994:Recombinant Proteins / Q000737:chemistry / Q000378:metabolism; D013154:Spleen
D005290:Ferric Compounds; D005609:Free Radicals; D011994:Recombinant Proteins; D017665:Hydroxyl Radical; D001052:Apoferritins; D007501:Iron; D002570:Ceruloplasmin; D006531:HEPES